Video

Clinical care pathway demonstrates efficacy for patients with overactive bladder

Author(s):

Urology Times staff

Chris Du, MD, discusses findings from a study published in Neurourology and Urodynamics.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this interview, Chris Du, MD, discusses findings from the Neurourology and Urodynamics paper, A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third‐line therapies?, for which he served as a study author. Du is a urology resident at Stony Brook University, Stony Brook, New York.

      More videos:

      Analysis underscores importance of pretreatment urine cultures in patients with recurrent UTI

      A primer for urologists on statutes of limitations

      What drives cystectomy-related malpractice lawsuits?


      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
      Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
      Mina Fam, MD, on managing expectations around testosterone replacement therapy
      Mina Fam, MD, on managing expectations around testosterone replacement therapy
      Justin Dubin, MD, on the role for AI in patient education
      Justin Dubin, MD, on the role for AI in patient education
      Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
      Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
      Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
      TMT for bladder cancer: Balancing cost and quality of life
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Justin Dubin, MD, on the use of AI in the male infertility space
      Justin Dubin, MD, on the use of AI in the male infertility space
      Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
      Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
      Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
      Investigators compare trimodal therapy vs cystectomy in MIBC
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Investigators assess ctDNA’s role in NMIBC
      Related Content
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
      July 9th 2025

      Leva System adds Mayo Clinic overactive bladder content

      Benjamin P. Saylor Hannah Clarke
      Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.
      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
      March 21st 2022

      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

      Urology Times staff
      “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
      Regulatory recap: FDA approvals in urology from the first half of 2025
      July 4th 2025

      Regulatory recap: FDA approvals in urology from the first half of 2025

      Hannah Clarke
      Take a look through all the regulatory milestones in urology from the first half of the 2025.
      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
      March 18th 2022

      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

      Urology Times staff
      “We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
      FDA updates in urology: June 2025
      July 1st 2025

      FDA updates in urology: June 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from June 2025.
      Howard B. Goldman, MD, FACS
      June 23rd 2025

      The future of OAB treatment: Emerging nerve targets and AI may guide therapy

      Howard B. Goldman, MD
      Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.
      © 2025 MJH Life Sciences

      All rights reserved.